Lenalidomide (Revlimid®, CC-5013) in Subjects With Relapsed or Refractory Indolent Non-Hodgkin's Lymphoma
- First Posted Date
- 2005-09-16
- Last Posted Date
- 2025-05-13
- Lead Sponsor
- Celgene
- Target Recruit Count
- 43
- Registration Number
- NCT00179673
- Locations
- 🇺🇸
Alta Bates Cancer Center, Berkeley, California, United States
🇺🇸Pacific Coast Hematology/Oncology Medical Group, Onc., Fountain Valley, California, United States
🇺🇸Swedish Cancer Institute, Seattle, Washington, United States
Lenalidomide Versus Placebo in Myelodysplastic Syndromes With a Deletion 5q[31] Abnormality
- Conditions
- Myelodysplastic Syndromes
- Interventions
- First Posted Date
- 2005-09-16
- Last Posted Date
- 2011-04-14
- Lead Sponsor
- Celgene Corporation
- Target Recruit Count
- 205
- Registration Number
- NCT00179621
- Locations
- 🇧🇪
AZ St-Jan Brugge AV, Brugge, Belgium
🇧🇪UZ Gasthuisberg, Leuven, Belgium
🇧🇪CHU Mont Godine, Yvoir, Belgium
Phase I/II Open-Label, Dose Escalation Study To Determine The Maximum Tolerated Dose And To Evaluate The Safety Profile of Lenalidomide (Revlimid® CC-5013) With Liposomal Doxorubicin In Subjects With Advanced Ovarian and Primary Peritoneal Carcinoma
- Conditions
- Ovarian Cancer
- First Posted Date
- 2005-09-16
- Last Posted Date
- 2006-04-12
- Lead Sponsor
- Celgene Corporation
- Target Recruit Count
- 60
- Registration Number
- NCT00179725
- Locations
- 🇺🇸
MD Anderson Cancer Center Orlando, Orlando, Florida, United States
🇺🇸OU Health Sciences Center, Oklahoma City, Oklahoma, United States
🇺🇸University of California at San Francisco, San Francisco, California, United States
A Multicenter, Single-Arm, Open-Label, Study to Evaluate the Safety and Efficacy of Single-Agent Lenalidomide (Revlimid, CC-5013) in Subjects With Androgen Independent Prostate Cancer.
- Conditions
- Prostate Cancer
- First Posted Date
- 2005-09-16
- Last Posted Date
- 2005-11-23
- Lead Sponsor
- Celgene Corporation
- Target Recruit Count
- 40
- Registration Number
- NCT00179738
- Locations
- 🇺🇸
Seattle Cancer Care Alliance, Seattle, Washington, United States
🇺🇸Alta Bates Cancer Center, Berkeley, California, United States
🇺🇸Roswell Park Cancer Institute, Buffalo, New York, United States
Phase I Open-Label, Dose Escalation Study To Determine The Maximum Tolerated Dose And To Evaluate The Safety Profile Of Lenalidomide (Revlimid®, CC-5013) With Pemetrexed In Subjects With Advanced Non-Small Cell Lung Cancer
- Conditions
- Non-Small Cell Lung Cancer
- First Posted Date
- 2005-09-16
- Last Posted Date
- 2005-11-07
- Lead Sponsor
- Celgene Corporation
- Target Recruit Count
- 40
- Registration Number
- NCT00179699
- Locations
- 🇺🇸
MD Anderson - Orlando, Orlando, Florida, United States
🇺🇸Washington University, St. Louis, Missouri, United States
🇺🇸North Shore Hem/Onc Associates, East Setauket, New York, United States
A Phase I/II Study of Lenalidomide in Combination With Gemcitabine in Patients With Untreated Advanced Carcinoma of the Pancreas
- Conditions
- Pancreatic Cancer
- First Posted Date
- 2005-09-16
- Last Posted Date
- 2005-11-07
- Lead Sponsor
- Celgene Corporation
- Target Recruit Count
- 50
- Registration Number
- NCT00179751
- Locations
- 🇺🇸
Sarah Cannon Cancer Center, Nashville, Tennessee, United States
🇺🇸Cancer and Blood Institute, Metairie, Louisiana, United States
🇺🇸Charleston Cancer Center, Charleston, South Carolina, United States
Expanded Access Program:Lenalidomide With or Without Dexamethasone In Previously Treated Subjects With Multiple Myeloma
- First Posted Date
- 2005-09-16
- Last Posted Date
- 2010-03-16
- Lead Sponsor
- Celgene Corporation
- Target Recruit Count
- 1913
- Registration Number
- NCT00179647
- Locations
- 🇺🇸
University of Texas Southwestern Medical Center, Dallas, Texas, United States
🇺🇸Mayo Clinic, Scottsdale, Arizona, United States
🇺🇸Cedar Sinai Medical CenterDept of Medicine, Los Angeles, California, United States
A Study to Evaluate the Single-Agent Lenalidomide in Subjects With Recurrent Non-Small-Cell Lung Cancer
- Conditions
- Non-Small Cell Lung Cancer
- First Posted Date
- 2005-09-16
- Last Posted Date
- 2006-12-20
- Lead Sponsor
- Celgene Corporation
- Target Recruit Count
- 40
- Registration Number
- NCT00179686
- Locations
- 🇺🇸
Cancer and Blood Institute, Metairie, Louisiana, United States
🇺🇸Rush Cancer Institute, Chicago, Illinois, United States
🇺🇸Birmingham Cancer Center, Birmingham, Alabama, United States
Study of the Combination of Lenalidomide and DTIC (Dacarbazine) in Patients With Metastatic Malignant Melanoma Previously Untreated With Systemic Chemotherapy
- Conditions
- Malignant Melanoma
- First Posted Date
- 2005-09-16
- Last Posted Date
- 2019-11-08
- Lead Sponsor
- Celgene
- Target Recruit Count
- 28
- Registration Number
- NCT00179608
- Locations
- 🇺🇸
MD Anderson Cancer Center, Houston, Texas, United States
A Phase I/II Study of ABI-007 (Abraxane®, Nab®-Paclitaxel)and Vinorelbine in Patients With Stage IV (Metastatic) Breast Cancer
- Conditions
- Stage IV (Metastatic) Breast Cancer
- Interventions
- First Posted Date
- 2005-09-01
- Last Posted Date
- 2019-11-26
- Lead Sponsor
- Celgene
- Target Recruit Count
- 16
- Registration Number
- NCT00140140
- Locations
- 🇺🇸
Seattle Cancer Care Alliance, Seattle, Washington, United States
🇺🇸City of Hope Comprehensive Cancer Care Center, Duarte, California, United States